Multi-modality therapy for cancer of the esophagus and GE junction (Q38010632)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on September 2012

Language	Label	Description	Also known as
English	Multi-modality therapy for cancer of the esophagus and GE junction	scientific article published on September 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Multi-modality therapy for cancer of the esophagus and GE junction (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Mohamedtaki A Tejani

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Barbara A Burtness

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

1 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Current Treatment Options in Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

390-402

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves es

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results.

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Vascular endothelial growth factor in esophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

(18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

A Prospective Study of Tobacco, Alcohol, and the Risk of Esophageal and Gastric Cancer Subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

21 January 2018

Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction chemoradiotherapy increases pleural and pericardial complications after esophagectomy for cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Impact of Time Elapsed Between Endoscopic Ultrasound and Esophagectomy on Concordance of Ultrasonographic and Pathologic Staging of Esophageal Malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of esophageal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22592595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11864-012-0193-5

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38010632&oldid=2201169632"